SCHEMBL1926314

SCHEMBL1926314

CC(C)(C)Nc1c(Nc2cc(Cl)ncn2)c(=O)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.42
PLK1 P53350 14/20 0.41
SGK1 O00141 1/20 0.41
PLK4 O00444 1/20 0.41
CHEK1 O14757 1/20 0.41
MAPK13 O15264 1/20 0.41
PDPK1 O15530 1/20 0.41
JAK2 O60674 1/20 0.41
ROCK2 O75116 1/20 0.41
CHEK2 O96017 1/20 0.41
FYN P06241 1/20 0.41
CSF1R P07333 1/20 0.41
MET P08581 1/20 0.41
PIM1 P11309 1/20 0.41
FLT1 P17948 1/20 0.41
FGFR3 P22607 1/20 0.41
MARK3 P27448 1/20 0.41
MAPK1 P28482 1/20 0.41
KDR P35968 1/20 0.41
FLT3 P36888 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2174911 0.78 NPC1 (0.45) NPC1MKNK1KMT2AMEN1WDR5
SCHEMBL1926261 0.76 PLK1 (0.47) NPC1PLK1SGK1PLK4CHEK1
SCHEMBL1926518 0.74 PLK1 (0.56) PLK1SGK1PLK4CHEK1MAPK13
SCHEMBL1925894 0.72 PLK1 (0.57) PLK1SGK1PLK4CHEK1MAPK13
SCHEMBL9962285 0.67 CXCR2 (0.40) PLK1SGK1PLK4CHEK1MAPK13
SCHEMBL25707106 0.65 L3MBTL1 (0.47) NPC1KDRMKNK1KMT2AMEN1
SCHEMBL18971573 0.65 LCK (0.54) NPC1FYN
SCHEMBL374406 0.65
SCHEMBL29382825 0.65
SCHEMBL1927335 0.64 ALDH1A1 (0.40) PLK1SGK1PLK4CHEK1MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956185-B2 Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases ABBOTT LABORATORIES (US) 2011-06-07 US disclosed
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES ABBVIE INC. 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES PLK1, PLK2, BUB1B NPC1 2020/4885PLK1 1/4885SGK1 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.